Phenylpyrrolidinone formyl peptide 2 receptor agonists
US-2020255375-A1 · Aug 13, 2020 · US
Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
US11186544B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11186544-B2 |
| Application number | US-201816619956-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 8, 2018 |
| Priority date | Jun 9, 2017 |
| Publication date | Nov 30, 2021 |
| Grant date | Nov 30, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of selected from the group consisting of or a pharmaceutically acceptable salt thereof. 2. A compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. 3. A compound selected from the group consisting of or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. 5. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. 6. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
Assignees
Inventors
Classifications
linked by a carbon chain containing aromatic rings · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a carbon chain containing aromatic rings · CPC title
linked by a carbon chain containing aromatic rings · CPC title
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11186544B2 cover?
- The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07D211/76. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).